Literature DB >> 19624982

Off-label indications for imiquimod.

Shahrouz Ganjian1, Ariel J Ourian, Gabreal Shamtoub, Jashin J Wu, Jenny E Murase.   

Abstract

Due to the ability of imiquimod (Aldara, 3M Pharmaceuticals) to rapidly and potently stimulate both innate and adaptive arms of the immune system, imiquimod has rapidly been recognized as a potential candidate for off-label use in over 60 conditions as presented in numerous case reports, letters, and small trials. It is our goal to examine and consolidate this impressive body of literature in order to provide the practicing dermatologist with a quick reference of the conditions that have been successfully treated with imiquimod, the dosages used, and the success rates of treatments.

Mesh:

Substances:

Year:  2009        PMID: 19624982

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  5 in total

Review 1.  Pattern recognition receptors in immune disorders affecting the skin.

Authors:  Heleen D de Koning; Anna Simon; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Innate Immun       Date:  2012-03-06       Impact factor: 7.349

Review 2.  Anal Intraepithelial Neoplasia and Squamous Cell Cancer of the Anus.

Authors:  Rebecca E Hoedema
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

3.  Development of imiquimod-loaded mucoadhesive films for oral dysplasia.

Authors:  Sandeep K Ramineni; Larry L Cunningham; Thomas D Dziubla; David A Puleo
Journal:  J Pharm Sci       Date:  2012-11-28       Impact factor: 3.534

4.  Current treatment options for management of anal intraepithelial neoplasia.

Authors:  Stephen E Weis
Journal:  Onco Targets Ther       Date:  2013-06-10       Impact factor: 4.147

5.  Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma.

Authors:  Goran Pancevski; Senada Pepic; Sanela Idoska; Gligor Tofoski; Suzana Nikolovska
Journal:  Open Access Maced J Med Sci       Date:  2018-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.